We serve 4-(Phthalimido)-Cyclohexanone CAS:104618-32-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: 4-(Phthalimido)-Cyclohexanone
CAS.NO: 104618-32-8
Synonyms:
4-Phthalimidocyclohexanone
2-(4-oxocyclohexyl)isoindole-1,3-dione
N-(4-Oxocyclohexyl)phthalimide
2-(4-Oxocyclohexyl)isoindoline-1,3-dione
Molecular Formula: C14H13NO3
Molecular Weight: 243.25800
Physical and Chemical Properties:
Density: 1.357 g/cm3
Boiling point: 409.96ºC at 760 mmHg
Melting point: /
Flash point:191.1±19.1 °C
Refractive index: 1.627
Specification:
Appearance: White off-white powder
Purity:≥98%
Packing:
25kg cardboard drum or according to customer specified requirements
Storage: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Pramipexole CAS:104632-26-0
Intermediates of Pramipexole dihydrochloride CAS:104632-25-9
Contact us for information like 4-(Phthalimido)-Cyclohexanone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(4-Oxocyclohexyl)isoindoline-1,3-dione physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(Phthalimido)-Cyclohexanone Use and application,4-(Phthalimido)-Cyclohexanone technical grade,usp/ep/jp grade.
Related News: The ban will be in place for up to 14 days, and is aimed at helping contain the spread of the Wuhan coronavirus. So far, there have been no confirmed coronavirus cases in New Zealand or any South Pacific island.2-Chloro-4,5-difluorobenzaldehyde manufacturer The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.Sulfuryl dichloride supplier The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.6,6-Dimethyl-3-azabicyclo[3.1.0]hexane vendor Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.
